BIND Biosciences Receives 2011 Edison Award

(Nanowerk News) BIND Biosciences announced today that it has been awarded a prestigious 2011 Edison Best New Product in Science and Medicine Game Changers Award. This award recognizes BIND's innovative targeted nanoparticle therapeutic platform for its potential to revolutionize the treatment of many serious diseases. The Edison Awards symbolize the persistence and excellence personified by Thomas Alva Edison, inspiring America's drive to remain in the forefront of innovation, creativity and ingenuity in the global economy.
BIND has rapidly translated cutting-edge science from its academic beginnings at the Massachusetts Institute of Technology and Harvard University to its first product candidate, currently in clinical development for the treatment of cancer. BIND is leveraging its proprietary Medicinal Nanoengineering® platform to advance a portfolio of product candidates into clinical development for the treatment of a number of serious diseases, including cancer, inflammatory diseases and cardiovascular disorders. BIND's nanoparticles target therapeutic payloads directly to diseased tissues and cells while minimizing off-target exposure, resulting in potentially more effective and less toxic medicines.
"We are honored to receive this award, which is a testament to the strength of our core technology platform and organization to make revolutionary drugs for important human diseases," said Scott Minick, BIND's CEO. "Our technology has the potential to create targeted therapeutics across a range of drug classes, including peptides, proteins, small molecules and siRNA. By complementing conventional medicinal chemistry approaches, BIND's targeted nanoparticle platform has demonstrated the potential to overcome many significant drug development challenges."
About The Edison Awards
The Edison Awards™ recognize the persistence and excellence Thomas Edison personified; qualities which have allowed America to remain in the forefront of innovation, creativity and ingenuity in the global economy. The Edison Awards are granted under the aegis of the Thomas Edison Papers at Rutgers University, a globally recognized research network dedicated to the study of innovation and its application in the 21st century. For more information about The Edison Awards, visit
About BIND Biosciences
BIND Biosciences, Inc. is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering® platform to produce best in class drugs. BIND's platform enables the design, engineering and manufacturing of targeted nanoparticle therapeutics with unprecedented control over drug PK, biodistribution and cell- or tissue-specific targeting. Medicinal Nanoengineering complements medicinal chemistry to enable predictable, cost effective, and rapid development of breakthrough products with superior efficacy and safety profiles. Product opportunities include enabling or expediting the development of pipeline molecules as well as improving performance, expanding indications, or life cycle extension for mid- and late-stage products. BIND's initial product development efforts are in the areas of oncology, inflammatory diseases and cardiovascular disorders. BIND's lead program, BIND-014, targets a surface protein upregulated in a broad range of solid tumors. BIND-014 is currently undergoing Phase I clinical testing in cancer patients.
BIND is backed by leading venture capital firms, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments and EndeavourVision. For more information, please visit the company's web site at
Source: BIND Biosciences (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: